Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sorry Chi-Chi ... back to ignore ... no more time for you

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon May 28, 2022 9:51am

187 Views

Post# 34714260

Sorry Chi-Chi ... back to ignore ... no more time for you

Now I have to put you back on "ignore."
The fun and games with kicking your tush in conversation are over.
I will be puting your other personality (Looking4) on the same "ignore" when you figure no one is listening to Chi-Chi.

The big boys and girls are getting ready to play again - time for me to say goodbye.

Bu-bye old friend

: )

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project